Crizona 250 mg (Crizotinib) Tablets

Crizona 250 contains Crizotinib, a targeted anticancer medicine used in specific types of non-small cell lung cancer (NSCLC). It works by blocking abnormal proteins that promote cancer cell growth and spread. This targeted approach may help slow disease progression and improve treatment outcomes in eligible patients. Crizona 250 is prescribed for patients with ALK-positive or ROS1-positive advanced NSCLC as determined by appropriate diagnostic testing. Treatment should be initiated and monitored by an experienced oncology specialist. Individual treatment response may vary depending on the patient's condition and medical history.

Each capsule contains Crizotinib INN 250 mg as the active pharmaceutical ingredient. Crizotinib belongs to the class of targeted anticancer medicines known as tyrosine kinase inhibitors (TKIs). The formulation is designed for oral administration and delivers a precise dose of the active compound. Inactive ingredients may include pharmaceutical excipients required for capsule formulation, stability, and absorption. Patients with known hypersensitivity to any component of the formulation should consult their healthcare provider before use. Always refer to the product packaging for complete composition details.

The recommended dosage and duration of treatment should be determined by a qualified healthcare professional based on the patient's medical condition and treatment response. Crizona 250 is generally administered orally and should be swallowed whole with water. It may be taken with or without food. Capsules should not be crushed, chewed, or opened. If a dose is missed, follow the physician's instructions and do not take a double dose to compensate. Regular medical monitoring may be required during treatment to assess effectiveness and safety. Always use this medicine exactly as prescribed by your